Literature DB >> 2944759

Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2'-deoxycoformycin.

J Epstein, P M Bealmear, D W Kennedy, M J Herrmann, A Islam, S C Wiedl.   

Abstract

Germ-free mice were used as a model for acute graft-versus-host disease (GVHD) in allogeneic bone marrow transplantation (BMT). C3H/He recipients of DBA/2 cells showed typical symptoms of acute GVHD and died within 8 days. Incubation of the cells with 10 microM 2'-deoxycoformycin (2dCF) + 100 microM deoxyadenosine (dAdo) for 1 h inhibited all T-cell functions as well as T-cell-dependent B-cell functions, but had no effect on B-cell functions that are T-cell independent, nor on the hemopoietic stem cells (CFU-S). Recipients of allogeneic cells that had been incubated with 2dCF + dAdo for 1 h prior to inoculation showed no signs, gross or histological, of acute or chronic GVHD up to 15 months after transplantation. The recovery patterns of the blood and bone marrow were not affected by the treatment, and were similar to those of recipients of treated and untreated syngeneic cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944759

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  3 in total

Review 1.  Current and emerging strategies for the prevention of graft-versus-host disease.

Authors:  Sung Won Choi; Pavan Reddy
Journal:  Nat Rev Clin Oncol       Date:  2014-06-24       Impact factor: 66.675

2.  Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.

Authors:  Simrit Parmar; Borje S Andersson; Daniel Couriel; Mark F Munsell; Marcelo Fernandez-Vina; Roy B Jones; Elizabeth J Shpall; Uday Popat; Paolo Anderlini; Sergio Giralt; Amin Alousi; Pedro Cano; Doyle Bosque; Chitra Hosing; Leandro de Padua Silva; Michael Westmoreland; J Kyle Wathen; Donald Berry; Richard E Champlin; Marcos J de Lima
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

3.  Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.

Authors:  Ming J Poi; Craig C Hofmeister; Jeffrey S Johnston; Ryan B Edwards; Buffy S Jansak; David M Lucas; Sherif S Farag; James T Dalton; Steven M Devine; Michael R Grever; Mitch A Phelps
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.